IRVINE, Calif. & CHICAGO--(BUSINESS WIRE)--BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it will host a “Lasers for Every Dentist” celebration as well as introduce its new, fifth-generation Waterlase Express™ all-tissue laser system at the Chicago Dental Society’s 152nd annual Midwinter Meeting February 23-25 at McCormick Place West. BIOLASE will also feature at the conference its new Epic Pro™ diode laser system now being sold in the U.S. and select international markets.
The “Lasers for Every Dentist” celebration will begin at 12 noon Central Time on Thursday, February 23 at the BIOLASE Booth (# 811). President and CEO Harold C. Flynn, Jr. will discuss the new BIOLASE products at the event, the Company’s efforts to train and support its customers and introduce other special guests including Dmitri Boutoussov, the Company’s Chief of Technology, and Samuel B. Low, DDS, the Chief Dental Officer and Vice President, Dental and Clinical Affairs.
The recently-launched Waterlase Express is the newest addition to the Company’s best-selling Waterlase® portfolio of Er,Cr:YSGG all-tissue lasers and represents the new foundation of the Company’s strategy to greatly expand all-tissue laser use in dentistry. Based on the Company’s proven Waterlase technology, the system is easy to learn and use, and is nearly one-quarter the size, one-third the weight, and half the U.S. retail price of the Company’s Waterlase iPlus system.
Waterlase Express offers several breakthroughs including such exciting new features as a familiar tablet interface with simple, elegant laser controls; a built-in, one-touch learning center; a rich onboard reference library; and a customer care button, all of which will help dentists new to all-tissue lasers integrate powerful Waterlase technology into their practices.
The Epic Pro, which was developed in partnership with IPG Medical Corporation, is an innovative new diode laser system that offers higher laser power than most diode lasers in dentistry. The newest addition to the Company’s Epic portfolio of soft-tissue diode lasers, Epic Pro offers important advancements in cutting speed, control, precision and improvements in consistency and predictability.
“The Chicago Mid-winter conference is an excellent platform to launch our new products, which have been designed with the guidance of our partners and teams of expert dentists and educators,” Flynn said. “These products provide our customers an easy to use laser solution for all their patient treatments. All dentists, even those completely new to lasers, can now easily learn to operate these new laser systems and all our Express customers will be supported by our one-touch access BIOLASE Customer Care™. Our goal is to continue to develop and market new, innovative products both internally and with outside partners like IPG Medical that will make laser technologies the standards of care in dentistry.”
Other highlights of the Chicago meeting include:
- Fully interactive exhibition and display
- Hands-on with the full BIOLASE laser portfolio
- Guest speakers featured in-booth throughout the meeting
- Meetings with key international partners and contributing clinicians
To learn more about the Waterlase Express system, the Epic Pro, and other innovations designed to simplify laser dentistry, visit www.biolase.com
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including digital x-rays and CAD/CAM scanners. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both dentists and their patients. BIOLASE's proprietary laser products incorporate approximately 255 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 32,800 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.
For updates and information on Waterlase® iPlus™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.
BIOLASE® and Waterlase® are registered trademarks of BIOLASE, Inc.
Product photography is available on request.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations regarding existing trends, and its strategic initiatives, and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.